Healthcare
•3734 stocks
•
Total Market Cap: Loading...
Apr 17, 2026
|
Bio‑Techne Announces New Brand Architecture to Streamline Customer Experience
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3734)
| Company | Market Cap | Price |
|---|---|---|
|
TEM
Tempus AI, Inc.
Laboratory Testing & Advisory Services – Tempus provides outsourced laboratory testing and regulatory/advisory support.
|
$9.94B |
$55.87
+2.66%
|
|
BAX
Baxter International Inc.
Novum IQ infusion platform is a medical device platform core to Baxter's Medical Devices & Equipment offerings.
|
$9.62B |
$18.71
+3.17%
|
|
MASI
Masimo Corporation
Primary revenue comes from patient monitoring devices and systems sold to healthcare providers.
|
$9.58B |
$178.42
+0.07%
|
|
AXSM
Axsome Therapeutics, Inc.
Axsome's revenue drivers Auvelity and Sunosi and pipeline products are oral small-molecule therapeutics.
|
$9.53B |
$189.08
+2.65%
|
|
ARWR
Arrowhead Pharmaceuticals, Inc.
Arrowhead's core platform and lead programs are based on RNA interference (siRNA) therapeutics, i.e., RNAi Therapeutics.
|
$9.44B |
$69.62
+2.42%
|
|
ICLR
ICON Public Limited Company
Directly describes ICON's outsourced drug development and management services as a Contract Research Organization.
|
$9.31B |
$119.58
+3.46%
|
|
HSIC
Henry Schein, Inc.
Henry Schein directly distributes dental equipment to dental practices, aligning with its core product offerings.
|
$9.28B |
$78.83
+2.10%
|
|
TECH
Bio-Techne Corporation
Bio-Techne's core business includes recombinant proteins and enzymes used as highly characterized reagents across life-science workflows.
|
$9.23B |
$59.24
+3.29%
|
|
VRNA
Verona Pharma plc
Verona's Ohtuvayre (ensifentrine) is a small-molecule therapeutic used for COPD management.
|
$9.10B |
$106.91
|
|
CRL
Charles River Laboratories International, Inc.
CRL operates as a contract research organization, outsourcing preclinical drug development services.
|
$9.05B |
$184.01
+4.00%
|
|
QGEN
Qiagen N.V.
QIAGEN directly manufactures diagnostic instruments (e.g., QIAstat-Dx, QIAcuity, QIAsymphony Connect) and automated platforms.
|
$8.98B |
$41.23
+0.65%
|
|
AHR
American Healthcare REIT, Inc.
Healthcare Services & Facilities: reflects management and operation of healthcare facilities within the portfolio.
|
$8.77B |
$49.58
-1.98%
|
|
ABVX
Abivax S.A.
Obefazimod is an oral small-molecule therapeutic targeting inflammatory pathways in IBD.
|
$8.76B |
$120.15
-1.89%
|
|
ATR
AptarGroup, Inc.
Aptar markets proprietary drug-delivery platforms (e.g., nasal/inhalation delivery) which are core to its pharma offering.
|
$8.57B |
$130.68
+1.86%
|
|
PRAX
Praxis Precision Medicines, Inc.
Praxis's Cerebrum platform develops oral small-molecule CNS therapies (e.g., ulixacaltamide, Vormatrigine).
|
$8.56B |
$343.00
+7.06%
|
|
BTSG
BrightSpring Health Services, Inc. Common Stock
Company operates home health and hospice services to patients in home and community settings.
|
$8.53B |
$47.27
+3.22%
|
|
BPMC
Blueprint Medicines Corporation
AYVAKIT is Blueprint Medicines' flagship oncology/hematology drug; directly produced and marketed, fitting Biotech - Oncology.
|
$8.27B |
$129.46
|
|
PCVX
Vaxcyte, Inc.
PCVX directly develops and is advancing vaccine products (VAX-24, VAX-31) including pneumococcal conjugate vaccines, making Vaccines the core investable product category.
|
$8.16B |
$62.34
+0.23%
|
|
CYTK
Cytokinetics, Incorporated
Cytokinetics' core programs target cardiovascular diseases (aficamten for hypertrophic cardiomyopathy, omecamtiv mecarbil and ulacamten), making 'Cardiovascular Drugs' the primary investable theme.
|
$8.16B |
$66.68
+1.93%
|
|
HALO
Halozyme Therapeutics, Inc.
Halozyme's ENHANZE is a proprietary drug-delivery platform enabling rapid, subcutaneous administration of large-volume biologics.
|
$8.15B |
$69.29
+3.98%
|
|
ESE
ESCO Technologies Inc.
Diagnostic Equipment reflects ESCO's diagnostic testing instruments and related software for measurement and monitoring.
|
$8.14B |
$315.08
+5.09%
|
|
BIO
Bio-Rad Laboratories, Inc.
Bio-Rad directly manufactures and sells diagnostic instruments and related equipment used in clinical laboratories.
|
$8.07B |
$299.06
+2.74%
|
|
KRYS
Krystal Biotech, Inc.
Krystal Biotech's core HSV-1 gene therapy platform and lead product VYJUVEK directly represent a gene therapy business.
|
$7.95B |
$274.26
+3.86%
|
|
NUVL
Nuvalent, Inc.
Nuvalent is a oncology-focused biotechnology company developing targeted cancer therapies (ROS1/ALK inhibitors), fitting Biotech - Oncology.
|
$7.82B |
$107.64
+3.64%
|
|
MOH
Molina Healthcare, Inc.
MOH primarily provides health insurance products (Medicaid, Medicare, Marketplace) including integrated dual-eligible plans.
|
$7.66B |
$148.92
+0.03%
|
|
IBRX
ImmunityBio, Inc.
Lead oncology-focused biotechnology with ANKTIVA and cancer immunotherapy platforms.
|
$7.58B |
$7.68
+6.00%
|
|
MTSR
Metsera, Inc.
Metsera is a clinical-stage biotech developing peptide-based therapeutics (MET-097i, MET-233i, MET-97o, MET-224o), i.e., Peptide Therapeutics.
|
$7.41B |
$70.53
+0.04%
|
|
GKOS
Glaukos Corporation
Glaukos directly manufactures ophthalmology devices, including iStent MIGS implants used in eye surgeries.
|
$7.17B |
$124.75
+2.57%
|
|
VOYA
Voya Financial, Inc.
VOYA provides health insurance products and related stop‑loss/health solutions to employers, a central part of its Workplace Solutions.
|
$7.08B |
$74.49
+2.31%
|
|
LNC
Lincoln National Corporation
LNC provides disability insurance as part of its group protection/employee benefits offerings.
|
$7.01B |
$36.90
+2.90%
|
|
MRUS
Merus N.V.
Company develops multispecific antibody therapeutics for oncology, including lead candidates like petosemtamab and BIZENGRI.
|
$6.81B |
$90.00
|
|
ACLX
Arcellx, Inc.
Company focuses on oncology therapeutics via engineered cell therapies, aligning with cancer treatment.
|
$6.65B |
$115.06
-0.03%
|
Showing page 6 of 38 (3734 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
